Vorinostat: Uses, Side Effects, and How It Works

Vorinostat, sold under the brand name Zolinza, is an oral cancer drug that works by blocking enzymes called histone deacetylases. It was the first drug in its class to receive FDA approval, granted in October 2006 for treating the skin symptoms of cutaneous T-cell lymphoma (CTCL) in patients whose disease has persisted or worsened after at least two other systemic treatments.¹ While its approved use is narrow, vorinostat has attracted research interest far beyond lymphoma, from brain tumors to HIV reservoirs to neurodegenerative disease.

How Vorinostat Works Inside Cells

Your DNA is wound around spool-like proteins called histones. Those histones can be chemically tagged in ways that either loosen or tighten the winding, which determines whether nearby genes get read or stay silent. One class of enzymes, histone deacetylases (HDACs), removes certain chemical tags from histones and generally keeps genes shut off. Vorinostat blocks all 11 known human class I and class II HDACs, which means it tips the balance toward opening up gene expression across a wide swath of the genome.²

When cancer cells are exposed to vorinostat, the result is a cascade of disruptions. One well-studied effect is a rise in p21, a protein that acts as a brake on cell division. In glioma cells, vorinostat increased p21 levels regardless of the status of p53, a common tumor-suppressor gene, and activated a checkpoint that stalled cells before they could divide further, ultimately pushing them toward programmed cell death.³ In lymphoma cells that had become resistant to rituximab and chemotherapy, vorinostat similarly boosted p21 and histone acetylation, arresting cells in the early phase of their growth cycle.⁴

Vorinostat does not only act on histones. In cutaneous T-cell lymphoma cells, it strongly suppressed production of interleukin-10, an immune-dampening molecule that CTCL cells frequently overproduce. It also nudged other immune signaling molecules in directions that could make tumors more visible to the immune system.⁵ This dual action, part direct cancer-cell killing, part immune reawakening, helps explain why CTCL was the first disease where vorinostat proved useful enough for regulatory approval.

The Approved Use in Cutaneous T-Cell Lymphoma

CTCL is a group of rare lymphomas in which cancerous white blood cells accumulate in the skin, causing patches, plaques, and sometimes tumors. Patients with advanced disease who have already tried multiple treatments have limited options, and vorinostat was approved specifically for them. The pivotal trial enrolled 74 patients with stage IB or higher CTCL who had failed at least two systemic therapies. At an oral dose of 400 mg once daily, the objective response rate was about 30%, with a median response duration of roughly 168 days and a median time to tumor progression of 202 days.¹ A second phase II trial in refractory advanced patients, including those with large-cell transformation and Sézary syndrome, produced overall response rates in the range of 24% to 30%.⁶

Those numbers sound modest, but context matters. These were patients who had already exhausted multiple lines of treatment, and a disease that primarily afflicts the skin creates enormous quality-of-life problems. In one multicenter trial, about a third of patients experienced meaningful relief from pruritus, the severe itching that often drives CTCL patients to seek new treatments in the first place.⁷ For patients with advanced CTCL, itch relief alone can be a significant win even if tumor burden does not fully respond.

How Vorinostat Compares to Newer Options

Vorinostat was the trailblazer in its drug class, but it is no longer the only game in town. A head-to-head phase III trial called MAVORIC compared vorinostat to mogamulizumab, an antibody drug, in previously treated CTCL patients. Mogamulizumab came out ahead, with a median progression-free survival of about 7.7 months compared to 3.1 months for vorinostat.⁸ That trial contributed to mogamulizumab’s approval for relapsed CTCL and shifted clinical practice in many centers.

Vorinostat still has a role, though. It is taken as a capsule at home rather than requiring infusion visits, and some patients who do not tolerate antibody-based treatments or who prefer an oral option still use it. Its side-effect profile, while not trivial, is manageable enough for long-term use in many patients, with dose reductions available if needed.

Common Side Effects

Pooled data from nearly 500 patients across clinical trials of vorinostat as a single agent or in combination paint a clear picture of what to expect. When used alone, the most frequently reported side effects were:

Fatigue: affected roughly 62% of patients, making it the most common complaint.
Nausea: affected about 56%.
Diarrhea: affected about 49%.
Loss of appetite: affected about 48%.
Vomiting: affected about 33%.

Most of these were mild or moderate in severity.⁹ The gastrointestinal symptoms tend to be the first things patients notice and the most common reason for dose adjustments. Taking vorinostat with food and staying well hydrated help, but they rarely eliminate these issues entirely.

Serious Side Effects and Lab Abnormalities

Beyond the gut-related complaints, vorinostat can cause blood count drops and metabolic problems that require monitoring. In the same pooled analysis, the most common severe (grade 3 or 4) side effects with single-agent vorinostat were fatigue in about 12% of patients, low platelet counts (thrombocytopenia) in roughly 11% to 16% when combining different measures, and dehydration in about 7%.⁹ The most common serious adverse event reported across studies was blood clots (thrombosis).¹⁰

Regular blood draws are standard for anyone on vorinostat. Doctors typically check complete blood counts and basic metabolic panels every couple of weeks during the initial period and then at wider intervals once the patient is stable. Low platelets can increase bleeding risk, and significant dehydration from persistent diarrhea can cascade into electrolyte imbalances. When these problems become severe, treatment is usually paused or the dose is lowered from 400 mg daily to 300 mg daily, or to 300 mg five days a week.

Combination Therapy in Other Cancers

Researchers have tested vorinostat alongside other drugs in cancers well beyond CTCL, with mixed results. In relapsed or refractory multiple myeloma, a phase I trial combining vorinostat with bortezomib found partial responses in about 27% of patients and disease stabilization in 59%, though all patients experienced some side effects. The combination was generally tolerable, with about 89% of adverse events classified as mild to moderate.¹¹

In newly diagnosed glioblastoma, a phase I/II trial combined vorinostat with the standard regimen of temozolomide and radiation. The overall survival rate at 15 months was about 55%, and the median overall survival was 16.1 months.¹² Those numbers were not dramatically better than what temozolomide and radiation achieve on their own, which is roughly 14 to 16 months of median survival, so vorinostat did not become part of the standard glioblastoma regimen.

Early-phase trials in solid tumors have also explored vorinostat followed by doxorubicin, a classic chemotherapy agent. In a small group of evaluable patients, one confirmed partial response was observed in a breast cancer patient, along with minor responses in melanoma and prostate cancer patients.¹³ Across all these solid-tumor efforts, the pattern has been the same: hints of activity in some patients, but nothing convincing enough to earn a new FDA indication.

Why Some Patients Stop Responding

Drug resistance is a practical concern for anyone taking vorinostat. Laboratory research has shown that cancer cells can develop acquired resistance to the drug at moderate levels, roughly a two- to three-fold shift in the concentration needed to kill them. In one detailed study using colon tumor cells, resistant cells lost the usual hallmarks of HDAC inhibitor activity: histones were no longer getting acetylated, cells no longer stalled at checkpoints, and the programmed cell death pathways stopped activating. Interestingly, the resistance was not caused by changes in the HDAC enzymes themselves.¹⁴

The same study found that vorinostat-resistant cells showed cross-resistance to some other HDAC inhibitors in the same chemical family, such as panobinostat and valproic acid, but remained sensitive to romidepsin and entinostat, which belong to different chemical classes. That finding has practical implications: if a patient’s CTCL stops responding to vorinostat, switching to romidepsin, another FDA-approved option for CTCL, may still work because the resistance mechanism does not necessarily extend to drugs with a different chemical backbone.

Predicting Who Will Benefit

One frustration with vorinostat in clinical practice is that only a minority of patients respond, and there is no reliable way to know in advance who those responders will be. Researchers have tried to identify biomarkers that could help. One candidate is a protein called HR23b, which helps shuttle proteins to the cell’s waste-disposal machinery. In mesenchymal tumor cell lines, sensitivity to vorinostat correlated significantly with HR23b protein levels: cells with high HR23b expression were more likely to be killed by the drug. This association was specific to vorinostat and did not hold for several other HDAC inhibitors tested.¹⁵

As promising as this sounds, HR23b testing has not yet become standard clinical practice. Validating a biomarker requires showing it works prospectively in actual patients, not just in lab dishes, and that large-scale confirmation has not been completed. For now, most oncologists rely on trial and error: start vorinostat, monitor skin lesions and symptoms, and reassess after a couple of months to decide if it is working.

Research Beyond Cancer

Vorinostat’s ability to switch genes on and off has attracted researchers studying diseases that have nothing to do with tumors. Two areas stand out: HIV cure research and neurodegenerative disease.

HIV Latency Reversal

HIV can hide silently inside resting immune cells, forming a latent reservoir that antiretroviral drugs cannot reach. The “shock and kill” strategy aims to use drugs like vorinostat to wake up the virus (the shock), making infected cells visible so the immune system or other interventions can destroy them (the kill). Vorinostat does appear to deliver the shock: in a clinical study, dosing every 72 hours produced a sustained increase in HIV RNA in the resting immune cells of most participants.¹⁶

The kill part is the problem. Modeling of in vivo data showed that while vorinostat activated viral transcription, it did not meaningfully increase the death rate of latently infected cells. In other words, the virus woke up but the cells harboring it did not die, and the reservoir did not shrink.¹⁷ Similarly, viral outgrowth assays after vorinostat dosing did not show convincing reductions in the reservoir.¹⁶ HIV researchers have largely moved on to combining latency-reversing agents with immune-boosting strategies rather than relying on vorinostat alone.

Neurological Conditions

Vorinostat stands out among HDAC inhibitors because it is one of the few that can be taken by mouth and still crosses into the brain.¹⁸ That property has made it an appealing candidate for repurposing in neurological diseases. Laboratory work has shown it can stimulate nerve cell outgrowth, a property that could theoretically help repair damaged neural circuits.¹⁹ In Alzheimer’s disease mouse models, low-dose dietary vorinostat increased brain histone acetylation and reduced oxidative stress.¹⁸

The list of brain disorders where vorinostat has shown preclinical promise is long: Alzheimer’s, Parkinson’s, Huntington’s, stroke, epilepsy, spinal muscular atrophy, and several others.²⁰ The gap between mouse studies and human therapies is enormous, though. Preclinical neurological research is littered with drugs that looked transformative in animals and did nothing for patients. No clinical trials have yet demonstrated that vorinostat helps humans with any neurological condition, and the side-effect profile described earlier, particularly the blood count drops and blood clot risk, would need careful weighing against any neurological benefit if trials do move forward.

Dosing Challenges in Younger Patients

Vorinostat was developed and approved in adults, but pediatric oncology has explored it as well. A Children’s Oncology Group phase I trial in children with solid tumors found the maximum tolerated dose to be 230 mg per square meter of body surface area per day, with dose-limiting problems including drops in white blood cells, platelets, and potassium levels at higher doses. One striking finding was the wide variability in how individual children processed the drug: blood levels at the same dose differed by more than six-fold between patients.²¹ That kind of variability makes dosing tricky and means pediatric patients need especially close monitoring.

Cost and Access Considerations

As an oral drug for a rare cancer, vorinostat comes with a high price tag. A systematic review of economic evaluations of epigenetic cancer drugs, including vorinostat, found that cost-effectiveness ratios varied wildly depending on the comparison and the cancer type, ranging from cost-saving in some scenarios to well over a million dollars per quality-adjusted life year gained in others.²² In practice, many patients in the United States access vorinostat through manufacturer assistance programs or specialty pharmacy channels. Insurance coverage varies, and prior authorization is almost always required given the drug’s narrow approved indication.

Generic versions of vorinostat have become available in some markets, which has lowered prices somewhat, but the drug remains expensive compared to most oral medications. For patients in countries without established reimbursement pathways for orphan oncology drugs, access can be genuinely difficult.

How Vorinostat Was Discovered

The story behind vorinostat is one of the more satisfying examples of serendipity in drug development. Researchers originally set out to understand why dimethylsulfoxide, a simple chemical solvent, caused certain virus-transformed mouse leukemia cells to mature and stop dividing. That basic-science question eventually led to the synthesis of suberoylanilide hydroxamic acid, later named vorinostat, and the realization that its target was the HDAC enzyme family.² The path from a curiosity about a lab solvent to an FDA-approved cancer drug took over three decades, a timeline that is unusually long even by pharmaceutical standards but reflects how fundamental the underlying biology turned out to be.